ESR1 and breast cancer: Considering intrinsic molecular profiling (PAM50) provides additional prognostic information for early‐stage ER+HER2− breast cancers [37, 38], we compared intrinsic subtypes distribution between grade I/II and III ER+HER2− tumors.